The effect of therapy of exjade and desferal on ferritin level in patients with major thalassemia
Phase 2
- Conditions
- Major Thalassemia.Beta thalassaemia
- Registration Number
- IRCT2015042114333N32
- Lead Sponsor
- Kermanshahu University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 90
Inclusion Criteria
Inclusion: being younger than 18; having thalasemia major based on observing clinical symptoms and hemoglobin electrophoresis history; being treated by deferoxamine hypodermic injection and ferritin level 1000 to 3000. Exclusion:inability to digest exjade; hepatitis virologic; LFT; active hepatitis; noncompliance with previous treatment regimens; ALT and AST normal up to 3 times
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Ferritin serum amount. Timepoint: at the beginning of the study and every 3 month for 6 months. Method of measurement: Using starfax device.
- Secondary Outcome Measures
Name Time Method